Rifampin is a prescription antibiotic used mainly to treat tuberculosis, and it has one of the better documented drug test interactions in the published laboratory literature. It can produce a false positive opiate result on a screening immunoassay, and separately it turns urine, sweat, saliva, and tears a yellow, orange, red, or brown color that can raise questions during a collection. Those are two different issues with two different explanations, and this article covers both along with what confirmation testing and the medical review officer process do with a result like this.
What rifampin is and how it is classified
Rifampin, also sold as rifampicin, is a semisynthetic antibiotic derived from rifamycin SV. It is prescribed for active tuberculosis, usually combined with other antibiotics, and for a small number of other bacterial infections and prophylaxis uses. It is a prescription only drug. The current current prescribing information, published through the National Library of Medicine's DailyMed database, does not list rifampin as a controlled substance, and it carries no Drug Enforcement Administration schedule. It is regulated as an antibacterial drug product, not as a drug of abuse.
That prescribing information is explicit that rifampin "may produce a discoloration (yellow, orange, red, brown) of the teeth, urine, sweat, sputum, and tears," and that soft contact lenses can be permanently stained. You can read the full label on DailyMed. That discoloration is pharmacologic, not a sign of injury or illness, but it is also exactly the kind of visible change a collector is trained to notice during specimen validity checks, so a donor on rifampin may be asked about it.
Which drug panel classes are affected
The documented interaction is with the opiate immunoassay, the screening test that looks for morphine, codeine, and related compounds on a standard 5, 10, or 12 panel test. A 2023 case report published in Practical Laboratory Medicine and indexed on PubMed Central describes a pediatric patient on rifampin therapy whose urine repeatedly screened positive for opiates on a kinetic interaction of microparticles in solution (KIMS) immunoassay run on a Roche Cobas analyzer, while every other drug class on the panel screened negative. You can read the case report on PubMed Central.
The report explains that immunoassays detect a compound by how well it binds to an antibody built to recognize opiates, and some unrelated or partially similar molecules can bind well enough to trigger a positive screen even though they are not opiates at all. That is cross reactivity, and it is a known limitation of immunoassay screening generally, not a defect specific to any one test brand. There is no published evidence of rifampin cross reacting with the amphetamine, cannabinoid, cocaine, benzodiazepine, PCP, barbiturate, or methadone immunoassay classes. If no cross reactivity evidence exists for a class, the honest statement is that there is no published cross reactivity for that class, not that it is impossible.
| Panel class | Documented rifampin cross reactivity | What confirmation testing found |
|---|---|---|
| Opiates (morphine, codeine) | Yes, published case report, KIMS immunoassay | HPLC confirmation negative for morphine, codeine, hydrocodone, hydromorphone, oxycodone, and related opiate metabolites |
| Amphetamines/methamphetamine | No published cross reactivity found | Not applicable |
| Cannabinoids (THC) | No published cross reactivity found | Not applicable |
| Cocaine metabolite, PCP, benzodiazepines | No published cross reactivity found | Not applicable |
| Specimen validity (color, creatinine, pH) | Urine, sweat, saliva, and tear discoloration documented on the official label | Collector notes appearance; discoloration alone is not evidence of adulteration |
How GC/MS or LC/MS confirmation resolves it
A screening immunoassay is a presumptive test built for speed and low cost, and it is designed to flag anything that might be a target drug rather than to prove it definitively. A presumptive positive on a federally regulated test, or on most employer programs that follow the same model, is never reported as a final result on its own. The specimen goes to a certified laboratory for confirmation by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS/MS), methods that identify the exact molecular structure of what is in the sample rather than relying on antibody binding. In the published case, confirmation by a chromatographic method was negative for morphine, codeine, hydrocodone, hydromorphone, 6 acetylmorphine, oxycodone, oxymorphone, and their related metabolites, even though the screen had flagged opiates twice. That is the expected outcome when a false positive is caused by cross reactivity rather than by actual opiate use, and it is why confirmation testing exists as a required step rather than an optional extra.
The MRO review and prescription documentation
For any test conducted under a federal drug testing program, the review process is set out in 49 CFR Part 40. A confirmed laboratory positive is not reported to the employer as positive until a medical review officer, a licensed physician trained in this review, has contacted the donor and asked about prescription and over the counter medications that could explain the result. The MRO has the authority to verify a test as negative if a legitimate medical explanation accounts for the finding, request supporting documentation such as a pharmacy record or prescriber's note, and determine whether any remaining question requires further lab consultation. The rules governing this review, including the MRO's duties and the verification process, are published in 49 CFR Part 40, Subpart G, with the full part available at eCFR Part 40. Non federally regulated employer programs generally use the same MRO model as a best practice, though program details vary by employer policy.
In practice, a donor who is taking rifampin should tell the collector and keep pharmacy documentation available. Since the published evidence involves the screening step and not the lab confirmation step, a true rifampin related false positive is expected to resolve once GC/MS or LC/MS confirmation is run, independent of what the donor discloses. Disclosure mainly helps the MRO move faster and document the explanation for the record.
What employers should do with a disputed result
An employer should never treat a presumptive immunoassay screen as a final verdict, and should never ask a donor to explain away a result informally instead of routing it through confirmation and MRO review. If a donor on rifampin raises the medication before or during collection, note it on the chain of custody form as the collector's training directs, and let the laboratory and MRO process run its course. Employers may be able to request that the MRO document the basis for a verified negative once confirmation and medical review are complete, but employers should not render their own medical judgment about whether a medication explains a screen, and should consult counsel on how to apply company policy to a disputed or delayed result. State and company policies vary on timelines and retest rights, so check the applicable policy and primary source before committing to a specific procedure.
Choosing the right test for opiate screening programs
Employers running their own 5, 10, or 12 panel opiate screening should expect that immunoassays, including cup and dip card formats, carry the same cross reactivity limitation described in the case literature. Programs that want fewer disputed screens should pair point of collection testing with a clear path to laboratory confirmation for any non negative result, rather than relying on the screen alone. American Screening Corporation's drug test cup collection is built around standard panel configurations designed to be paired with confirmation testing when a screen comes back non negative.
For background on how collectors evaluate a specimen's appearance and validity markers like color, temperature, and creatinine, see our guide to specimen validity testing. For a full walkthrough of how a positive screen moves through verification, see the medical review officer process.
Frequently asked questions
Does rifampin show up as an opiate on a drug test?
It can trigger a presumptive positive on the opiate immunoassay screen, as documented in a published case report. It is not an opiate, and GC/MS or LC/MS confirmation testing has been shown to resolve the presumptive positive as negative for morphine, codeine, and related opiate compounds.
Is rifampin a controlled substance?
No. The current prescribing information on DailyMed does not list rifampin under any Drug Enforcement Administration schedule. It is a prescription antibacterial drug, not a controlled substance.
Why does rifampin turn urine orange or red?
The official label states that rifampin can discolor teeth, urine, sweat, sputum, and tears yellow, orange, red, or brown. This is a known pharmacologic effect of the drug itself and is separate from the opiate immunoassay cross reactivity issue.
Will rifampin cause a false positive for THC, cocaine, or amphetamines?
There is no published cross reactivity evidence connecting rifampin to those immunoassay classes. The documented interaction is specific to opiate screening.
How does a lab confirm whether an opiate result is real?
Certified laboratories run gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry on any non negative screen. These methods identify the exact compound present rather than relying on antibody cross reactivity, and they are the step that distinguishes a true opiate positive from a cross reactive false positive.
What should someone taking rifampin do before a drug test?
Tell the collector about the prescription and keep pharmacy documentation available. If the screen comes back non negative, the medical review officer will review prescription information as part of the standard verification process under 49 CFR Part 40.
This article is general information about drug testing science and procedure, not medical or legal advice. Anyone with questions about a specific medication or test result should talk to a healthcare provider, a medical review officer, or qualified counsel.
